XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

Smith & Nephew shares soar as activist Cevian builds stake



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Smith & Nephew shares surge on activist Cevian building stake</title></head><body>

Cevian's 5% stake to make it no.2 shareholder in S+N

S+N shares rise to top of FTSE 100

Cevian sees potential by improving operating performance

S+N says will continue talks with Cevian

Adds analyst quote in paragraphs 10-11

By Yadarisa Shabong

July 4 (Reuters) -Shares in Smith & Nephew SN.L rose 7% to the top of the FTSE 100 index on Thursday after activist investor Cevian Capital disclosed a 5% stake in the British medical equipment maker, a filing showed.

Cevian, whose newly disclosed holding would make it Smith & Nephew's second largest shareholder according to LSEG data, is known for taking stakes in companies and calling for change.

Smith & Nephew, which makes orthopaedic implants, wound dressings and other surgical materials, has lost more than 50% of its stock value from an all-time high hit in February 2020.

Pandemic lockdowns that led to surgery delays and supply-related disruptions from COVID times, as well as high raw material costs due to the Russia-Ukraine conflict, have taken a toll on the company, which has struggled to grow its margins.

"Smith & Nephew owns fundamentally attractive businesses in structurally growing markets, but the company has not generated shareholder value for many years," Friederike Helfer, a partner at Cevian Capital, said in a statement.

"Cevian sees the potential to create significant long-term value by improving the operating performance of the company’s businesses. We have high expectations for the board and management to realize this potential," he added.

Smith & Nephew's FTSE 100 shares have struggled to eke out yearly gains for the past four years.

The group said it would continue to engage with Cevian "as we dowith all of ourshareholders", without providing further details as the conversations are private.

In 2022, it started a transformation plan that aimed to grow its hip and knee implant, wound management and sports medicines businesses while expanding margins.

"Cevian is likely to hold management's feet to the fire and may look for more ambitious targets than set out under the existing improvement plan," AJ Bell analyst Russ Mould said.

"It could also push for a rationalisation of the company’s portfolio."

Cevian is No.3 shareholder in Irish building materials firm CRH CRH.N, which last year ditched its primary London listing in favour of New York.

It is also the top shareholder in global education group Pearson PSON.L, which had reportedly faced investor pressure last year to move its listing.

Cevian sold down its entire stake in British insurer Aviva AV.L last year and ended its campaign to drive up investor payouts at the FSTE 100 company.

Smith & Nephew shares were up 7% to 1,057 pence by 1016 GMT.



Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman, Nivedita Bhattacharjee and Jan Harvey

</body></html>

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.